Treats inflammatory lesions of non-nodular moderate to severe acne vulgaris. Sold as Seysara. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Sarecycline Hydrochloride (sold as Seysara), first approved Oct 1, 2018, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Seysara | Part D | $849K | +8% | 193 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
